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Abstract
Background The CONTROL Surveillance Project was a
comprehensive patient-based survey conducted among
hypothyroid patients undergoing treatment. The primary
objective of the study was to specifically quantify the
prevalence of factors adversely affecting levothyroxine
therapy.
Methods Participants were selected from a large propri-
etary database. Those eligible for the study completed a
21-question survey.
Results Of the eligible hypothyroid patients, 925
(92.5 %) were being treated with levothyroxine
monotherapy. The mean age was 60.4 years; 755 (81.6 %)
were female and 168 (18.2 %) were male. Almost half of
those receiving levothyroxine (435, 47.0 %) had at least
one comorbid condition that could adversely affect its
absorption: gastroesophageal reflux disease (33.8 % of
patients), irritable bowel syndrome (9.7 %), lactose intol-
erance (7.8 %), or a history of gastric bypass surgery or
bowel resection (3.0 %). Other factors reported by many
patients that could adversely affect levothyroxine absorp-
tion included use of prescription medications (20.6 %) and
over-the-counter medications (34.3 %) used to treat
comorbid gastrointestinal (GI) conditions; use of dietary
supplements (51.8 %, primarily calcium and iron); and
intake of foods/beverages high in fiber, iodine, or soy
(68.0 %). Of the 13.4 % who reported difficulty controlling
their hypothyroid symptoms, significantly more patients
with comorbid GI conditions reported such difficulty (7.8
versus 5.6 %, P\ 0.01). Frequent changes in levothyrox-
ine dosing (two or more dose changes in the past year)
were reported by 8.0 % of survey participants. Those with
GI comorbidities were nearly twice as likely to have such
changes (5.0 versus 3.0 %, P\ 0.01).
Conclusion Better initial workup of patients, including
identification of relevant GI comorbidities and allergies,
may help in the early detection of factors that may affect
the performance of levothyroxine.
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Key Points
This study documented the prevalence in
hypothyroid patients of factors known to affect
levothyroxine efficacy and tolerability.
The results suggest that there is room for improved
dialogue between physicians and patients regarding
the proper administration of levothyroxine and the
avoidance of foods and drugs that complicate its use.
For patients receiving higher-than-recommended
doses of levothyroxine, a complete patient re-
evaluation is recommended to determine the
presence of factors that affect the ability of
levothyroxine to achieve desired therapeutic results.
Adopting these steps may improve patients’ quality
of life and reduce the financial burden placed on the
healthcare system, resulting from the frequent
physician and pharmacy visits, medication
adjustments, laboratory tests, and poor compliance
associated with levothyroxine therapy.
1 Introduction
1.1 Background and Study Rationale
Hypothyroidism often results from autoimmune thyroid
disease or thyroid resection [1, 2]. In the majority of cases,
hypothyroidism can be treated effectively by oral thyroid
hormone supplementation, most commonly with levothy-
roxine. Typically, patients require 1.6–1.8 lg of levothy-
roxine per kilogram of body weight, although lean body
mass is a better criterion for dosing, with typical doses
being 2–3 lg/kg [3–6].
Key factors adversely affecting levothyroxine perfor-
mance have been widely reported in the clinical literature.
They include comorbid conditions and their treatments,
diet, tolerability of medication, and compliance with
instructions for administration [7–18].
When levothyroxine is taken in a fasting state, up to
80 % of it can be absorbed [19].
However, the absorption of levothyroxine can be limited
by a variety of diseases of the gastrointestinal (GI) tract,
including inflammatory bowel disease (IBD), atrophic gas-
tritis, celiac disease, Helicobacter pylori infection, gastroe-
sophageal reflux disease (GERD), lactose intolerance, and
gastroparesis, among others. The presence of these condi-
tions may adversely affect levothyroxine absorption and
thereby affect its dose requirements [7–12, 15–18, 20].
Additional factors that have been shown to affect
levothyroxine absorption and performance—some of
which may be related to the diseases of the GI tract noted
above—include excess body weight; poor compliance with
therapy; diet; gastric bypass surgery (reduced or delayed
absorption); and use of certain nutritional supplements,
vitamins, and medications, such as proton pump inhibitors,
histamine receptor blockers, cholestyramine, and motility-
modifying agents [7, 8, 12–17].
1.2 Study Objectives
The primary objective of the CONTROL Surveillance
Project was to specifically quantify the prevalence of fac-
tors that are known to adversely affect levothyroxine per-
formance, including:
• The prevalence of GI conditions known to affect drug
absorption.
• Sensitivity to inactive ingredients contained in tablet
drug formulations (i.e., excipients).
• Consumption of prescription and non-prescription
medications, vitamins, foods, and beverages known to
interfere with levothyroxine therapy.
• Patient understanding and compliance with levothyrox-
ine administration guidelines (e.g., timing before and
after meals).
2 Methods
2.1 Survey Development/Selection of Patients
The survey’s content was developed as a cooperative effort
between Akrimax Pharmaceuticals, LLC (Cranford, NJ,
USA; the study sponsor) and Healthcare Research and
Analytics, LLC (HRA; Parsippany, NJ, USA). HRA pro-
grammed the questionnaire into an online instrument via its
Confirmit tool.
Prior to the full launch of the survey, it was tested to
ensure that recording of data was consistent with the sur-
vey’s questions and screening criteria. All survey responses
were recorded confidentially, with the study sponsor being
blinded to the responses of individual participants.
Participants were selected from a large proprietary
database from Research Now. Research Now identified
individuals with a self-reported diagnosis of primary
hypothyroidism and recruited potential survey respondents
for this online quantitative study via e-mail invitations
from their proprietary ‘‘By-Invitation-Only’’ panel. Each
person contacted was assigned an individual ID for
recording his or her entire survey participation history,
including ‘‘Did not meet inclusion/exclusion criteria’’.
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Those who accepted the invitation to take part in the
survey were provided with a link to access the survey web
page, where they were provided with information about the
project, the anonymity of the survey’s findings, an outline
of what study subjects were required to do, and the time
required. Subjects were informed that every attempt would
be made to ensure the confidentiality of their data, and they
were given a statement indicating that participation was
voluntary and that withdrawal from the survey was possible
at any stage.
Qualified subjects then completed the 21-question sur-
vey online (see ‘‘Appendix’’). Subjects received an hono-
rarium or gratuity (as termed by Research Now) of
US$20, based on the length of time a subject took to
complete the survey online and the sample type, in keeping
with the panel membership policies of Research Now.
The honorarium or gratuity did not exceed the agreed-upon
amount set by the study sponsor or exceed the industry
standards for market research among this sample type.
Respondents received their honoraria/gratuities upon
completion of the survey.
The survey was initiated on March 27, 2015, and com-
pleted on April 8, 2015.
2.2 Sample Size and Inclusion/Exclusion Criteria
The study was designed to be exploratory, and all statistical
tests were performed to provide hypotheses for future
research. The primary intent of the study was to gather data
through a patient survey for better understanding of the
prevalence of factors that are known to affect the perfor-
mance of levothyroxine therapy. A pre-survey power
analysis determined that a sample size of 1000 subjects
would be sufficient to obtain estimates of prevalence rates
that reflect the prevalence of certain GI conditions in the
target population, with a 95 % confidence interval. For
conditions such as GERD and H. pylori infection, whose
prevalence in the general population is relatively high
(15–40 %) [9, 10, 13], a sample size of 1000 subjects
would provide an estimated 95 % confidence interval of
±2–3 %. For conditions with a low prevalence (e.g., a
condition with a 0.75 % prevalence reported in the litera-
ture), such as Crohn’s disease or ulcerative colitis [13], a
sample size of 1000 subjects would provide an estimated
95 % confidence interval of ±0.53 %.
2.2.1 Inclusion Criteria
Each subject was required to meet all of the following
criteria:
• Being treated with prescription medication for
hypothyroidism.
• At least 19 years of age.
• US resident.
• Voluntary agreement to provide informed consent.
• Able to read English.
• Willing and able to complete the survey.
2.2.2 Exclusion Criteria
Any subject who met the following criterion was excluded:
• Not taking prescriptionmedication to treat hypothyroidism.
2.3 Survey Completion and Quality Assurance
Patients entered their answers online. If a patient did not
complete the survey, i.e., did not progress to the last
question and enter an answer, his or her survey was
recorded as incomplete and the answers were not included
in the results. Incomplete surveys were categorized sepa-
rately from survey terminations (patients disqualified
through screening questions). More information regarding
the survey completion and quality assurance process is
presented in Table 1.
2.4 Data Management, Tabulations, and Statistical
Analyses
The survey questions incorporated multiple choice/closed-
ended questions, either ‘‘single punch/single select’’ or
‘‘multiple punch/select all that apply’’. Some questions
included an open-ended option, ‘‘Other (specify: …)’’.
Coding of all answers, data checks, summary tabulations,
and statistical analyses of the data, including tests of sig-
nificance for hypothesis testing, were performed by HRA.
All were exploratory in nature, and no adjustments for
multiple comparisons were made. The Quantum software
package (IBM, Armonk, NY, USA) was used for all phases
of data processing, online data collection sources, and
SPSS-generated data.
Table 1 Survey completion and quality assurance features
Feature
Personal computers used by patients
Clicking on survey link = unique respondent
Answers required for each question before proceeding
Return to previous questions not allowed
Survey exit without completing all questions = incomplete
Following survey submission, return to survey not allowed
Assignment of unique ID plus RVID programming prevented
further access from same computer
RVID relevant ID
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For continuous data, the number of subjects, mean,
standard deviation, median, minimum, and maximum were
calculated. Where appropriate, statistical tests were per-
formed for hypothesis-testing purposes. Demographic data
for the sample are presented by age, gender, and race.
2.5 Study Ethics
The protocol and appropriate related documents were
reviewed and approved by IntegReview IRB (Austin, TX,
USA), constituted and functioning in accordance with US
federal guidelines [21].
The study was conducted in accordance with the stan-
dard operating practices of the study sponsor, Akrimax,
which are designed to ensure adherence to Good Clinical
Practice (GCP) guidelines [21].
Each subject was informed that participation in the study
was voluntary and that he or she could withdraw from the
study at any time. A waiver of informed consent was issued
by IntegReview IRB, in accordance with US federal
guidelines [22].
Research Now and HRA followed all national, regio-
nal, and local laws with respect to privacy and data pro-
tection. Research Now ensured that the survey complied
with all applicable industry standards set by the Council of
American Survey Research Organizations (USA) and the
Market Research Association (USA).
Secure servers at Research Now were used to carry out
the collection of survey data. Personal information was
fully protected. Sampling teams did not have direct access
to the database that might have revealed the identity of
users. The survey remained anonymous and linked to the
subject database using numeric IDs to ensure protection of
the identity of each subject, and, as discussed above, to
prevent unauthorized access to the survey and multiple
participations by individual subjects.
3 Results
3.1 Survey Completion Rates
Sixty-six percent of invited subjects (1000/1506) qualified
for, and completed, the survey. Such a high percentage was
most likely attributable to the ability of Research Now to
target subjects who had been previously self-identified as
hypothyroid patients. There were 320 incomplete surveys
and 186 survey terminations.
3.2 Demographics
Of the 1000 patients who completed the survey, 925
(92.5 %) were receiving levothyroxine monotherapy.
Others were being treated either with a combination of
levothyroxine and other hypothyroid medications or with
non-levothyroxine therapies. The mean age of patients
receiving levothyroxine monotherapy was 60.4 years
(range 19 to[75 years; 8 % were aged C75 years, 30 %
were aged 65–74 years, 37 % were aged 55–64 years, and
15 % were aged 45–54 years). Most respondents [755
(81.6 %)] were female; only 168 (18.2 %) were male (two
respondents declined to specify gender). Over 90 % of
respondents were Caucasian (Table 2). Nearly two-thirds
(62.9 %) had been taking hypothyroid medication for more
than 10 years.
3.3 Prevalence of Relevant Comorbid Diseases/
Conditions and Use of Concomitant Medications
The prevalence of comorbid diseases or conditions that
could adversely affect the absorption of levothyroxine was
substantial and generally consistent with that reported in
the medical literature for the population at large [9–13, 16,
23] (Table 3).
A substantial number of hypothyroid patients reported
taking medications for comorbid GI conditions—either
prescription medications (20.6 %) or over-the-counter
(OTC) medications (34.3 %)—that could also adversely
affect the absorption of levothyroxine (Tables 4, 5).
3.4 Other Key Factors Affecting Levothyroxine
Performance
Certain dietary supplements are known to cause malab-
sorption of levothyroxine [7, 8, 13, 15, 17]. Overall,
51.8 % of patients indicated that they frequently take one
or more such dietary supplements, with calcium supple-
ments (47.5 %) and iron supplements (11.9 %) being most
frequently reported.
A majority (68.0 %) of patients indicated that they fre-
quently (more than twice weekly) eat food or consume
beverages that are known to cause malabsorption of
levothyroxine. These include high-fiber foods (bran flakes,
broccoli, fiber bars, fiber drinks), foods high in iodine
(dried seaweed, cranberries, lobster, cod, plain yogurt), and
soy-based foods.
More than 20 % of patients reported taking levothy-
roxine during breakfast or later in the day, including during
lunch or dinner. Many patients (21.5 %) reported taking
levothyroxine less than the recommended 30 min before
eating.
Of the 925 patients who were receiving levothyroxine,
112 (12.1 %) reported experiencing GI upset (nausea,
stomach cramps, or diarrhea) when taking it.
Overall, 15.2 % of patients receiving levothyroxine
reported allergies to one or more excipients that are known
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to be included in most tablet drug formulations. Those
most frequently reported were allergies to lactose (11.9 %),
gluten (3.78 %), and food dyes and sucrose (1–2 % each).
3.5 Control of Symptoms
Lack of hypothyroid symptom control was reported by survey
respondents. Of the 124 patients (13.4 %) reporting difficulty
controlling their hypothyroid symptoms, significantly more
patients with comorbid GI conditions who were taking
levothyroxine reported difficulty with symptom control, ver-
sus those without such conditions (P\ 0.01) [Table 6].
3.6 Changes in Hypothyroid Medication/Changes
in Levothyroxine Dose
More than 80 % of surveyed patients reported having had
at least one change in their prescribed hypothyroid medi-
cation since beginning therapy. Many patients (16.0 %)
reported 5–10 changes, and 6.1 % reported having [10
Table 2 Racial and ethnic distribution of survey participants
Total [n (%)] Hypothyroidism w/o
GI condition [n (%)]
Hypothyroidism w/GI
condition [n (%)]
Total 925 490 435
Non-Hispanic White or Euro-American 867 (94) 454 (93) 413 (95)
Black, Afro-Caribbean, or African American 13 (1) 5 (1) 8 (2)
Latino or Hispanic American 17 (2) 8 (2) 9 (2)
East Asian or Asian American 13 (1) 11 (2) 2 (*)
South Asian or Indian American 4 (*) 3 (1) 1 (*)
Middle Eastern or Arab American 3 (*) 3 (1) – (–)
Native American or Alaskan Native 5 (1) 2 (*) 3 (1)
Mixed race 2 (*) 2 (*) – (–)
Prefer not to answer 9 (1) 6 (1) 3 (1)
Total mentions 933 494 439
Some respondents specified more than one category
w/GI with gastrointestinal, w/o GI without gastrointestinal
*\1 %
Table 3 Prevalence of relevant concomitant diseases/conditions in
hypothyroid patient population receiving levothyroxine (n = 925)
Concomitant disease/condition n (%)
Acid reflux or GERD 313 (33.8)
IBS 90 (9.7)
Food allergies 85 (9.2)
Lactose intolerance 72 (7.8)
Gastric bypass or bowel resection 28 (3.0)
H. pylori infection 19 (2.1)
Gastroparesis 15 (1.6)
Celiac disease 10 (1.1)
Ulcerative colitis 10 (1.1)
Crohn’s disease 6 (0.6)
Atrophic gastritis 1 (0.0)
Othera 157 (17.0)
None of the above 488 (52.8)
Because patients could specify more than one concomitant disease or
condition, the total for the last column exceeds 100 %
GERD gastroesophageal reflux disease, IBS irritable bowel syndrome
a Other = numerous gastrointestinal and non-gastrointestinal conditions
Table 4 Hypothyroid patients on levothyroxine (n = 925) receiving
medication for relevant concomitant diseases/conditions
Concomitant disease/condition n (%)
Acid reflux or GERD 246 (26.6)
IBS 28 (3.0)
Food allergies 11 (1.2)
Lactose intolerance 9 (1.0)
Gastric bypass or bowel resection 8 (0.9)
Gastroparesis 7 (0.8)
Ulcerative colitis 6 (0.6)
Crohn’s disease 5 (0.5)
Atrophic gastritis 1 (0.1)
Celiac disease 1 (0.1)
H. pylori infection 1 (0.1)
Othera 139 (15.0)
None of the above 607 (65.6)
Because patients could specify medication for more than one con-
comitant disease or condition, the total for the last column exceeds
100 %
GERD gastroesophageal reflux disease, IBS irritable bowel syndrome
a Other = numerous gastrointestinal and non-gastrointestinal conditions
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changes. As presented in Fig. 1, the overall number of self-
reported changes in hypothyroid medication since the
beginning of treatment with levothyroxine was comparable
between those with and those without comorbid GI
conditions.
While many participants in the CONTROL Surveillance
Project had been on levothyroxine for several years, many
(31.4 %) reported a change in levothyroxine dose within
the past year. Among patients experiencing C2 levothy-
roxine dose changes during the past year, those with self-
reported GI comorbidities had nearly twice the prevalence
of the other patients (P\ 0.01) [Fig. 2].
3.7 Quality-of-Life Factors and Self-Reported
Patient Satisfaction
While the CONTROL Surveillance Project was not
designed to measure quality of life, nearly 11 % of
respondents indicated that their thyroid condition ‘‘reduced
their quality of life’’ and ‘‘rendered them unable to do the
things they used to do’’. Similarly, 28.4 % of all respon-
dents indicated that their thyroid condition limited their
ability to ‘‘take on any activity or task’’. Overall, 16.6 % of
patients indicated that they have been ‘‘unable to live life
normally since undergoing treatment for hypothyroidism’’.
A minority of respondents reported ever discussing with
their physician topics such as the proper administration of
hypothyroid medication (44.4 %), concomitant use of
prescription medications (29.5 %), concomitant use of
OTC medications (12.6 %), use of dietary or food sup-
plements (10.9 %), or the presence of stomach or GI
conditions (10.0 %) or food allergies (4.1 %) that may
interfere with levothyroxine therapy.
Overall, 19.6 % of patients stated that they are not fully
satisfied with their hypothyroid treatment. Significantly
more patients with comorbid GI conditions reported dis-
satisfaction with their thyroid treatment, versus those
without such conditions (P\ 0.05) (Table 7).
4 Discussion
Many factors contribute directly or indirectly to the failure
of levothyroxine therapy. These can adversely affect
treatment satisfaction and can lead to unnecessary con-
sumption of healthcare resources in the form of increased
physician and pharmacy visits, laboratory costs, and med-
ication adjustments [24–33].
The CONTROL Surveillance Project is one of the most
comprehensive patient-based surveys ever conducted
among hypothyroid patients. It has helped to document the
prevalence of factors that can complicate levothyroxine
therapy. Unlike previous community-based surveys or
retrospective analyses of patient medical records [3, 34,
35], CONTROL Surveillance attempted to measure the
influences that diet, OTC medication use, and the degree of
adherence to levothyroxine administration guidelines (be-
fore or after meals) may have on levothyroxine therapy.
Such information is rarely, or only sporadically, recorded
in patient records.
Table 5 Numbers of hypothyroid patients on levothyroxine
(n = 925) who were taking antacids or acid reducers[2 times/week
Antacid or acid reducer n (%)
Prescription acid reducer – (–)
Proton pump inhibitora 180 (19.5)
Histamine (H2)-receptor blocker
b 0 (0.0)
Non-prescription acid reducer – (–)
Proton pump inhibitora 83 (9.0)
Histamine (H2)-receptor blocker
b 53 (5.7)
Non-prescription antacidsc 168 (18.2)
Other non-prescription antacid or acid reducerd 13 (1.4)
Other prescription antacid or acid reducere 11 (1.2)
None of the above 543 (58.7)
Because patients could specify more than one medication, the total for
the last column exceeds 100 %
a Esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole
b Cimetidine, ranitidine
c Multiple brands
d Other non-prescription antacids or acid reducers = generics of
multiple products
e Other prescription antacids or acid reducers = generics of multiple
products






Completely or somewhat agree 52 (5.6) 72 (7.8) 124 (13.4)
Slightly agree or disagree 438 (47.4) 363 (39.2) 801 (86.6)
Total 490 (53.0) 435 (47.0) 925
Chi-square test P value:\0.01
w/GI with gastrointestinal, w/o GI without gastrointestinal
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The results of the CONTROL Surveillance Project
quantify the prevalence of GI disorders that can inhibit the
absorption of levothyroxine and necessitate frequent
levothyroxine dose adjustments. Of the 925 hypothyroid
patients surveyed who were currently taking levothyroxine,
435 (47.0 %) had at least one commonly prevalent GI
disease or condition. The prevalence rates of GERD, irri-
table bowel syndrome (IBS), gastroparesis, and a history of
gastric bypass surgery or bowel resection were generally
consistent between those found in the CONTROL
Note: 88 (9.5%) of patients having hypothyroidism w/o GI conditions and 71 (7.7%) of patients w/GI conditions reported never having a change
in their hypothyroid medication; 26 (2.8%) of patients having hypothyroidism w/o GI conditions and 12 (1.3%) of patients w/GI conditions did not















Hypothyroidism w/o GI Condition        Hypothyroidism w/GI Condition    
5-10 dose changes >10 dose changes
Fig. 1 Total number of changes in hypothyroid medication since initiation of therapy
















Chi-Square Test P-value: <0.01. w/GI with gastrointestinal, w/o GI without gastrointestinal
Fig. 2 Number of changes in
dose of levothyroxine in the past
year
Table 7 Patients indicating their level of agreement with the statement ‘‘I am satisfied with my hypothyroid treatment’’
Hypothyroidism w/o




Completely or somewhat agree 407 (44.0) 337 (36.4) 744 (80.4)
Slightly agree or disagree 83 (9.0) 98 (10.6) 181 (19.6)
Total 490 (53.0) 435 (47.0) 925
Chi-square test P value:\0.05
w/GI with gastrointestinal, w/o GI without gastrointestinal
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Surveillance Project and those reported in the literature for
general patient populations [9–13, 16, 23]. It should be
noted that the age range (from 19 to[75 years) and mean
age (60.4 years) of the patient population in this survey
mirror those of the hypothyroid population reported in the
medical literature and in clinical practice [36], which
would be expected with such a large sample of patients
who self-identified as having this condition.
In comparison with all other patients in this study, sig-
nificantly more of those who had such GI disorders
reported difficulty achieving control of their hypothyroid
symptoms (P\ 0.01). Similarly, a relationship between
these commonly prevalent GI conditions and the need for
levothyroxine dose adjustment was noted. Participants
experiencing C2 levothyroxine dose changes in the past
year were more likely to have one or more of these
conditions.
Hypothyroid patients requiring increased doses of
levothyroxine have been well documented in the medical
literature and in clinical practice [37]. Data from five dif-
ferent studies have shown that non-optimal levothyroxine
therapy, resulting in thyroid-stimulating hormone (TSH)
levels above (or below) the reference range, is common,
ranging from 32 to 48 % of patients [38–42].
In a study by Vaisman et al. [42], questionnaires were
used to evaluate levothyroxine replacement treatment in
patients with primary hypothyroidism being followed in
referral centers in Brazil. Among all patients taking thyroid
medication, 42.7 % had an abnormal serum TSH level
(28.3 % were undertreated and 14.4 % were overtreated).
The investigators concluded that a significant number of
patients taking thyroid hormones are not in the therapeutic
range, on the basis of TSH assays. Clinicians should,
therefore, consider monitoring patients on thyroid
replacement more frequently and provide patients with
more precise recommendations about proper use of
levothyroxine.
Viga´rio et al. [43] performed a cross-sectional study
involving 2057 patients receiving levothyroxine replace-
ment for primary hypothyroidism at four referral centers in
Brazil. The results showed that a total of 14.4 % of patients
were overtreated (13.0 % with subclinical hyperthyroidism
and 1.4 % with overt hyperthyroidism). The prevalence of
undertreatment was 25.9 % (21.5 % with subclinical
hypothyroidism and 4.4 % overt hypothyroidism). The
investigators concluded that undertreatment of hypothy-
roidism is associated with poor patient health-related
quality of life (especially physical and emotional aspects),
and adequate levothyroxine therapy should always be
given to maintain serum TSH levels within the reference
range.
It is also interesting to note that more than 20 % of
patients in our survey reported taking levothyroxine during
breakfast or later in the day, including during lunch or
dinner. Many patients (21.5 %) reported taking levothy-
roxine less than the recommended 30 min before eating.
Inappropriate timing of ingestion may have contributed to
less-than-optimal levothyroxine performance in these
patients.
In a randomized, double-blind, crossover trial involving
90 patients, however, Bolk et al. [44] found that levothy-
roxine taken at bedtime rather than in the morning signif-
icantly improved thyroid hormone levels. These
investigators recommended that clinicians consider pre-
scribing levothyroxine intake at bedtime.
Regarding gastric bypass surgery, its impact on the
absorption of levothyroxine can vary, depending on the
procedure [23]. Rubio et al. [45] evaluated the absorption
of levothyroxine in morbidly obese patients before
(n = 15) and after (n = 15) a Roux-en-Y surgical proce-
dure. Although bypass surgery did not diminish the
absorption of levothyroxine in this study, a small but sig-
nificant delay in the absorption of levothyroxine was
observed in patients following surgery.
4.1 Comparisons with Prior Patient Surveys
The CONTROL Surveillance Project extends the findings
of two earlier, more limited, surveys among treated
hypothyroid patients [34, 35]. In 1977, the Whickham
Survey [34] determined the prevalence of overt hypothy-
roidism to be 1.4–1.9 % in females and 0.1 % in males in a
general population of 2779 (mean age 47 years) in County
Durham, England. In 2006, Wilson et al. [35] conducted
another community-based, cross-sectional survey in the
UK, involving 5690 subjects aged 65 years and older—the
Birmingham Elderly Survey. The investigators reported
prevalence rates of 0.4 % for overt hypothyroidism and
2.9 % for subclinical hypothyroidism. In obtaining subject
demographic information, the investigators reported the
overall prevalence rates of GI diseases to be 0 % in sub-
jects with overt hypothyroidism and 1.8 % in subjects with
subclinical hypothyroidism. However, the sample sizes of
the two groups were small (n = 23 and n = 168, respec-
tively), and the GI diseases were not categorized system-
atically. In both surveys, there was no attempt to document
the prevalence of factors [such as diet, medication con-
sumption (prescription and non-prescription), and patient
behaviors] that are known to affect the performance of
levothyroxine.
4.2 Study Limitations
The CONTROL Surveillance Project was controlled and
powered to determine statistically meaningful results and
to provide key insights into important issues surrounding
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levothyroxine treatment in hypothyroid patients. But, given
the lack of control over patient inclusion by race, among
other reasons, its findings should be considered more
hypothesis generating than conclusive. Because this was a
patient survey with no access to patient records, certain
data, such as thyroid hormone levels, were not available to
assist in interpretation of the results. The high percentage
of Caucasian respondents in CONTROL Surveillance is not
consistent with the racial mix of the hypothyroid popula-
tion at large reported in the published literature [46].
However, the overrepresentation of Caucasians is consis-
tent with the results reported in other patient survey panels.
Knapton and Myers [46] have reported the tendency of
many non-Caucasians to have lower response rates to
online surveys; the reasons for it are unclear.
5 Conclusion
Levothyroxine has been the ‘‘gold standard’’ treatment for
hypothyroidism for over 60 years. It is one of the most
frequently used medications in the USA, with over
115 million prescriptions dispensed in 2013 [47].
Notwithstanding the ubiquitous use of levothyroxine, there
have been few surveys that address the prevalence of
commonly cited reasons for its frequently suboptimal
performance.
The CONTROL Surveillance Project documents the
prevalence of factors that are well known to affect
levothyroxine efficacy and tolerability. GI comorbidities,
concomitant drug use, and dietary habits that complicate
levothyroxine therapy may be more prevalent among
treated hypothyroid patients than is generally understood.
Similarly, allergies to excipient ingredients found in most
tablet drug formulations may also be more common than is
generally perceived. The frequency of levothyroxine dose
changes, the need for unexpectedly high doses, and the
inability of levothyroxine to control the symptoms of
hypothyroidism have been shown to correlate with the
presence of these factors [48].
The results of the CONTROL Surveillance Project
suggest that there is room for improved dialogue between
physicians and patients regarding the proper administration
of levothyroxine and the avoidance of foods and drugs that
complicate its use. In particular, better initial workup of
patients (including identification of relevant comorbidities
and allergies) may help to detect factors that can lead to
suboptimal efficacy or tolerability of levothyroxine. For
patients already on levothyroxine therapy who are receiv-
ing doses that are higher than those recommended by
current treatment guidelines [49], a complete patient re-
evaluation is recommended to determine the presence of
factors that affect the ability of levothyroxine to achieve
desired therapeutic results [50–52]. Adopting these addi-
tional steps may improve the quality of life for patients and
reduce the financial burden placed on the healthcare system
that results from the frequent physician and pharmacy
visits, medication adjustments, laboratory tests, and poor
compliance associated with levothyroxine therapy.
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Appendix
n. <<S1 OTHER>>
o. None of the above MUTUALLY EXCLUSIVE
S3.  Which of the following thyroid medicaons are you currently taking?  (Select all that apply.)








i. WP Thyroid® 
j. Generic levothyroxine 
k. Other (specify:___________) TERMINATE IF ONLY OTHER IS SELECTED
S4. What is your age?




SURVEY LENGTH:  10-15 MINUTES (21 QUESTIONS)
QUOTA:  1000 PATIENTS
SCREENER
S1.  Please indicate which of the following, if any, medical condions you have been diagnosed with 
and/or procedures you have had.  (Select all that apply.)
a. Acid reﬂux or GERD
b. Atrophic gastris
c. Celiac disease 
d. Crohn's disease (inﬂammaon aﬀecng the enre digesve tract)
e. Food allergies
f. Gastric bypass or bowel resecon
g. Gastroparesis (slows/stops the movement of food from the stomach)
h. H. pylori infecon (a bacteria that infects the stomach)
i. Hypothyroidism (underacve thyroid) TERMINATE IF NOT SELECTED
j. Hyperthyroidism (overacve thyroid) I  &  J  ARE MUTUALLY EXCLUSIVE
k. IBS (irritable bowel syndrome)
l. Lactose intolerance
m. Ulcerave colis (inﬂammaon aﬀecng the colon/large bowel)
n. Other (specify:___________)
o. None of the above MUTUALLY EXCLUSIVE
SHOW ONLY OPTIONS SELECTED IN S1
S2.  For which of the following, if any, are you currently taking medicaon(s) prescribed by your doctor?
(Select all that apply.)
a. Acid reﬂux or GERD
b. Atrophic gastris
c. Celiac disease 
d. Crohn's disease (inﬂammaon aﬀecng the enre digesve tract)
e. Food allergies
f. Gastric bypass or bowel resecon
g. Gastroparesis (slows/stops the movement of food from the stomach)
h. H. pylori infecon (a bacteria that infects the stomach)
i. Hypothyroidism (underacve thyroid) TERMINATE IF NOT SELECTED
j. Hyperthyroidism (overacve thyroid) I  &  J  ARE MUTUALLY EXCLUSIVE
k. IBS (irritable bowel syndrome)
l. Lactose intolerance
m. Ulcerave colis (inﬂammaon aﬀecng the colon/large bowel)






h. I don’t know
3. Have you ever stopped taking your prescribed hypothyroid medicaon for more than one month
(past or present prescripon)? 
a. Yes
b. No
ASK IF Q3 = Yes
4. When you re-started your hypothyroid medicaon which one of the following were you 
prescribed? (Select one)
a. The same dose of the same brand of hypothyroid medicaon you were taking before
b. A diﬀerent dose of the same brand of hypothyroid medicaon you were taking before
c. A diﬀerent brand of hypothyroid medicaon than you were taking before
ASK IF Q3 = Yes
5. Which of the following were reason(s) you stopped taking your hypothyroid medicaon for more 
than one month?  (Select all that apply.)
RANDOMIZE
a. Felt beer, no need to take medicine
b. Medicaon too expensive
c. My brand was not available at pharmacy
d. Insurance company wouldn’t cover
e. Prefer a non-drug remedy
f. Medicine made me feel worse
g. Other 
6. Have you ever, past or present, experienced upset stomach or gastrointesnal (GI) upset (i.e. 
experienced symptoms like nausea, stomach cramps, diarrhea) when taking your hypothyroid 
medicaon?  (Select one.)
Never Rarely Somemes Oen Always
MAIN QUESTIONNAIRE
1. Since you were ﬁrst diagnosed with hypothyroidism, how long have you been taking hypothyroid 
prescripon medicaon(s) to treat the condion?  (Select one.)
a. Less than 6 months
b. About 6-12 months
c. About 1-2 years
d. About 3-5 years
e. About 6-10 years 
f. More than 10 years 
2. Since you ﬁrst started taking hypothyroid prescripon medicaon(s), how many mes has your 
prescribed hypothyroid medicaon been changed? (Select one.)
a. Never
b. 1 me
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TO BE CORRELATED WITH TREATMENT AND PHYSICIAN DISCUSSION
7. What type of doctor currently prescribes your hypothyroid medicaon? (Select one.)




8. How many mes in the past year, has your current doctor changed the dose of your current








9. When do you typically take your hypothyroid medicaon? 
ALLOW RESPONDENT TO SELECT AT ANY TICK MARK; ALLOW UP TO TWO SELECTIONS
Wake up Breakfast Mid-morning Lunch Aernoon Dinner Aer Dinner Bedme




ASK IF Q10 = Before eang
11. How much me, before eang, do you typically take your hypothyroid medicaon?  (Select one.)
a. Less than 10 minutes before eang
b. 10-19 minutes before eang
c. 20-29 minutes before eang
d. 30-39 minutes before eang
e. 40-49 minutes before eang
f. 50-59 minutes before eang
g. 1-2 hours before eang
h. More than 2 hours before eang
ASK IF Q10 = Aer eang
12. How much me, aer eang, do you typically take your hypothyroid medicaon?  (Select one.)
a. Less than 10 minutes aer eang
b. 10-19 minutes aer eang
c. 20-29 minutes aer eang
d. 30-39 minutes aer eang
e. 40-49 minutes aer eang
f. 50-59 minutes aer eang
g. 1-2 hours aer eang
h. More than 2 hours aer eang
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13. With regard to hypothyroid treatment, which of the following, if any, have you ever discussed 






d. Use of OTC medicaons
e. Use of other prescripon medicaons
f. Stomach or gastrointesnal condions 
g. Thyroid medicaon use (i.e., the proper way to take the medicaon, limitaons, etc.)
h. None of the above MUTUALLY EXCLUSIVE
14. With regard to hypothyroid treatment, which of the doctor-provided resources are most 
important to you? (Please rank in order of importance, where 1 = The most important resource, 2 






d. Disease state informaon
e. Informaon about support groups
f. Informaon about online resources
15. Thinking of your overall experience of being treated for hypothyroidism, please indicate your level 
of agreement with the following statements:
DO NOT RANDOMIZE 








1. Nobody seems to understand or care 
about how I feel
2. I don’t know where to get reliable 
informaon about my thyroid 
condion
3. It’s hard to control my hypothyroid 
symptoms
4. My thyroid condion reduces my 
quality of life causing me not to be 
able to do the things I used to do
5. I am able to take on anything without 
being limited by my thyroid condion 
6. I am sasﬁed with my hypothyroid 
treatment 
7. I can live life normally 
16. Please indicate which of the following antacid or acid reducers, if any, you take on a frequent basis 
(more than 2 mes per week).  (Select all that apply.)
NOTE:  PRODUCTS ARE TO BE GROUPED ON THE BACKEND UNDER NON-PRESCRIPTION ANTACIDS, 
PRESCRIPTION ANTACIDS, AND PRESCRIPTION ACID REDUCERS.  DO NOT SHOW THESE GROUPS, 
RED TEXT, TO RESPONDENT.
a. AcipHex® PRESCRIPTION ACID REDUCERS
b. Alka-Seltzer® NON-PRESCRIPTION ANTACIDS
c. Gaviscon® NON-PRESCRIPTION ANTACIDS
d. Maalox® NON-PRESCRIPTION ANTACIDS
e. Nexium®, non-prescripon NON-PRESCRIPTION ACID REDUCERS
f. Nexium®, prescripon PRESCRIPTION ACID REDUCERS
g. Pepto-Bismol® NON-PRESCRIPTION ANTACIDS
h. Prevacid®, non-prescripon NON-PRESCRIPTION ACID REDUCERS
i. Prevacid®, prescripon PRESCRIPTION ACID REDUCERS
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j. Prilosec®, non-prescripon NON-PRESCRIPTION ACID REDUCERS
k. Prilosec®, prescripon PRESCRIPTION ACID REDUCERS
l. Protonix® PRESCRIPTION ACID REDUCERS
m. Rolaids® NON-PRESCRIPTION ANTACIDS
n. Tagamet HB 200® NON-PRESCRIPTION ACID REDUCERS
o. Tums® NON-PRESCRIPTION ANTACIDS
p. Zantac® NON-PRESCRIPTION ACID REDUCERS
q. Other non-prescripon antacid or acid reducers (specify:___________) TBD, POST CODING
r. Other prescripon antacid or acid reducers (specify:___________) TBD, POST CODING
s. I do not take any antacid or acid reducers on a frequent basis MUTUALLY EXCLUSIVE
17. Which of the following dietary supplements, if any, do you take on a frequent basis (more than 2 




d. None of the above MUTUALLY EXCLUSIVE
18. Which of the following, if any, do you eat/drink more than 2 mes per week?  (Select all that 
apply.)
a. Soy-based foods (i.e., soy beans, soy milk, tofu, etc.)
b. Grapefruit / grapefruit juice
c. Foods high in ﬁber (i.e. bran ﬂakes, broccoli, ﬁber bars, ﬁber drinks, etc.)
d. Foods high in iodine (i.e. dried seaweed, cranberries, lobster, cod, plain yogurt etc.)
e. None of the above MUTUALLY EXCLUSIVE







f. Other (specify:___________[OE  - text]
g. I do not suﬀer from any food allergies HIDE IF S1_D IS SELECTED; MUTUALLY EXCLUSIVE
20. What is your gender?
a. Male
b. Female
c. Prefer not to answer
21. Which of the following best represents your racial or ethnic heritage? (Select all that apply)
a. Non-Hispanic White or Euro-American
b. Black, Afro-Caribbean, or African American
c. Lano or Hispanic American
d. East Asian or Asian American
e. South Asian or Indian American
f. Middle Eastern or Arab American
g. Nave American or Alaskan Nave
h. Other (please specify)___________________________ (OE – text)
i. Prefer not to answer
[END SURVEY]
Thank you for your parcipaon in this survey!
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